2 completed, 1 withdrawn. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow RPh201: new trials by email Literature Review of RPh201 trials Research Report on RPh201
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease RPh201, Placebo - Mild to Moderate Dementia Due to Alzheimer's Disease, With or Without Coexisting Cerebrovascular Disease | Phase 2 | Completed | Regenera Pharma Ltd | 83 | 2018-03-01 | 2020-04-30 |
| Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION). RPh201, Placebo - Non-arteritic Ischemic Optic Neuropathy, Optic Nerve Injuries | Phase 2 | Completed | Regenera Pharma Ltd | 22 | 2014-02-01 | 2020-03-19 |
| The Impact of RPh201 on CVS Patients: Clinical and fMRI Measurements RPh201, saline - Chronic Vegetative State | Phase 1 / Phase 2 | Withdrawn | Hadassah Medical Organization | 2011-10-01 | 2015-09-22 |
Alzheimer Disease (1) · Dementia (1) · Optic Nerve Injuries (1) · Optic Neuropathy, Ischemic (1) · Persistent Vegetative State (1)
Regenera Pharma Ltd (2) · Hadassah Medical Organization (1)
Canada (1) · Israel (1)
Sharon Cohen, MD (1) · Tamir Ben-Hur, MD PhD (1) · Zvi Segal,, MD (1)